BioParity.UFO / UAP research

14 sources for “Scientific background”

Results

PaperS7558

Mass cytometry as a platform for the discovery of cellular biomarkers to guide effective rheumatic disease therapy

Nitya Nair, Henrik E. Mei, Shih-Yu Chen, Matthew Hale, Garry P. Nolan, Holden T. Maecker, Mark Genovese, C. Garrison Fathman, Chan C. Whiting. ebi.ac.uk. May 18, 2015.

This 2015 review discusses mass cytometry as a possible aid to rheumatic-disease research. Its preliminary illustration compares one patient with one healthy control; concurrent treatment and assay timing limit interpretation. The authors explicitly consider residual drug neutralizing added TNF as an alternative to changed cell signaling. The illustration does not establish a validated biomarker or clinical recommendation. Nolan is a verified coauthor, while detailed individual contribution roles are not supplied.

Complete supplied review text and figures read
PaperS7563

Joint Modeling and Registration of Cell Populations in Cohorts of High-Dimensional Flow Cytometric Data

Saumyadipta Pyne, Sharon X. Lee, Kui Wang, Jonathan Irish, Pablo Tamayo, Marc-Danie Nazaire, Tarn Duong, Shu-Kay Ng, David Hafler, Ronald Levy, Garry P. Nolan, Jill Mesirov, Geoffrey J. McLachlan. ebi.ac.uk. July 1, 2014.

JCM models and registers cell populations across preprocessed flow-cytometry samples. Its demonstrations reuse three prior datasets, with manual gates, selected panels and selected benchmark samples. The implemented model restricts the general formulation. Exploratory results and nested cells do not establish prospective clinical prediction or independent replication. Nolan contributed materials, tools and writing. Source inconsistencies in timing, marker counts, tables, references and equations remain unresolved.

Complete supplied main and static supplements read

A curated public selection. Source review describes what was read; it does not establish that a claim is true. Our research approach